MetaCap

Gossamer Bio (GOSS) vs Polaryx Therapeutics (PLYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Polaryx Therapeutics is the larger company by market cap ($66.3 million vs $65.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOSS-94.60%PLYX-96.20%
+13%-44%-101%
Feb 2, 20261 yearNov 20, 2026
GOSS-94.07%PLYX-85.07%
+6%-47%-100%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOSS versus PLYX key metrics
MetricGOSSPLYX
Share price$10.72$1.33
Market cap$65.57M$66.30M
1-day change-4.54%-11.92%
YTD return-95.68%—
1-year return-95.62%—
5-year return-98.74%—
EPS (TTM)$-42.41$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$48.47M—
Revenue growth (YoY)-57.74%—
Net income (latest FY)$-170.37M$-8.98M
Operating margin-352.23%—
Net margin-351.49%—
52-week high$309.60$48.91
52-week low$8.29$1.30
Distance from 52-week high-96.54%-97.28%
Analyst consensusbuynone
Avg. price target upside+669.40%+463.91%
Average volume243.40K36.42K
Shares outstanding6.12M49.85M
Employees1612
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

GOSS vs PLYX FAQ

Which is bigger, Gossamer Bio or Polaryx Therapeutics?

Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $66.30M compared with $65.57M for Gossamer Bio (GOSS).

Are Gossamer Bio and Polaryx Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons